1. Home
  2. BLFY vs DMAC Comparison

BLFY vs DMAC Comparison

Compare BLFY & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BLFY
  • DMAC
  • Stock Information
  • Founded
  • BLFY 1939
  • DMAC 2000
  • Country
  • BLFY United States
  • DMAC United States
  • Employees
  • BLFY 179
  • DMAC N/A
  • Industry
  • BLFY Commercial Banks
  • DMAC Biotechnology: Pharmaceutical Preparations
  • Sector
  • BLFY Finance
  • DMAC Health Care
  • Exchange
  • BLFY Nasdaq
  • DMAC Nasdaq
  • Market Cap
  • BLFY 238.0M
  • DMAC 228.3M
  • IPO Year
  • BLFY N/A
  • DMAC N/A
  • Fundamental
  • Price
  • BLFY $10.12
  • DMAC $4.97
  • Analyst Decision
  • BLFY Hold
  • DMAC Strong Buy
  • Analyst Count
  • BLFY 2
  • DMAC 3
  • Target Price
  • BLFY $11.50
  • DMAC $7.00
  • AVG Volume (30 Days)
  • BLFY 38.7K
  • DMAC 155.8K
  • Earning Date
  • BLFY 01-22-2025
  • DMAC 11-13-2024
  • Dividend Yield
  • BLFY N/A
  • DMAC N/A
  • EPS Growth
  • BLFY N/A
  • DMAC N/A
  • EPS
  • BLFY N/A
  • DMAC N/A
  • Revenue
  • BLFY $40,112,000.00
  • DMAC N/A
  • Revenue This Year
  • BLFY N/A
  • DMAC N/A
  • Revenue Next Year
  • BLFY $16.19
  • DMAC N/A
  • P/E Ratio
  • BLFY N/A
  • DMAC N/A
  • Revenue Growth
  • BLFY N/A
  • DMAC N/A
  • 52 Week Low
  • BLFY $7.90
  • DMAC $2.14
  • 52 Week High
  • BLFY $11.48
  • DMAC $5.74
  • Technical
  • Relative Strength Index (RSI)
  • BLFY 43.13
  • DMAC 53.46
  • Support Level
  • BLFY $10.42
  • DMAC $5.06
  • Resistance Level
  • BLFY $10.93
  • DMAC $5.74
  • Average True Range (ATR)
  • BLFY 0.22
  • DMAC 0.34
  • MACD
  • BLFY -0.08
  • DMAC -0.04
  • Stochastic Oscillator
  • BLFY 15.68
  • DMAC 25.79

About BLFY Blue Foundry Bancorp

Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

Share on Social Networks: